Milton Packer
About
In The Last Decade
Milton Packer
641 papers receiving 63.0k citations
Hit Papers
Peers
Comparison fields: 5 of 182
- Cardiology and Cardiovascular Medicine 52.9k
- Endocrinology, Diabetes and Metabolism 10.6k
- Surgery 9.4k
- Pulmonary and Respiratory Medicine 8.5k
- Molecular Biology 7.3k
Countries citing papers authored by Milton Packer
This map shows the geographic impact of Milton Packer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milton Packer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milton Packer more than expected).
Fields of papers citing papers by Milton Packer
This network shows the impact of papers produced by Milton Packer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milton Packer. The network helps show where Milton Packer may publish in the future.
Co-authorship network of co-authors of Milton Packer
This figure shows the co-authorship network connecting the top 25 collaborators of Milton Packer. A scholar is included among the top collaborators of Milton Packer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milton Packer. Milton Packer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 2 | |
| 6 | 5 | |
| 7 | 0 | |
| 8 | 3 | |
| 9 | 15 | |
| 10 | 3 | |
| 11 | Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial breakdown → | 46 |
| 12 | 1 | |
| 13 | 10 | |
| 14 | 39 | |
| 15 | 3 | |
| 16 | 11 | |
| 17 | 32 | |
| 18 | 180 | |
| 19 | 178 | |
| 20 | Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF) breakdown → | 339 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.